Effects of Intra-vitreal Injection of Bevacizumab as an Adjunct during Phacoemulsification in Diabetic Maculopathy

Doi: 10.36351/pjo.v37i1.1122

  • Ali Afzal Bodla Multan Medical and Dental College, Multan and Bodla Eye Care
  • Syeda Minahil Kazmi Department of Ophthalmology, Multan Medical and Dental College, Multan
  • Noor Tariq Department of Ophthalmology, Multan Medical and Dental College, Multan
  • Ayema Moazzam Department of Ophthalmology, Multan Medical and Dental College, Multan
  • Muhammad Muneeb Aman Department of Ophthalmology, Multan Medical and Dental College, Multan
Keywords: Diabetes mellitus; diabetic macular edema; diabetic retinopathy: Bevacizumab.

Abstract

Purpose:  To study the effects of Intra-vitreal injection of Bevacizumab as an adjunct during phacoemulsification in patients with diabetic retinopathy.

Study Design:  Quasi experimental study.

Methods:  Hundred diabetic patients who were scheduled to undergo phacoemulsification were included in the study. They were equally divided into two groups; Bevacizumab and control group. Complete ocular examination and macular thickness and volume were determined using an OPTOVUE-OCT machine. The patients in the Bevacizumab group were given intra-vitreal injection of 1.25 mg/0.05ml of Bevacizumab at the time of Phacoemulsification. A written ethical approval was obtained and the study was conducted according to principles of declaration of Helsinki.

Results:  The bevacizumab group manifested low value of CMT one month post-surgery as compared to the control group (262.2 ± 32.2 and 288.5 ± 54.1, respectively) with P = 0.01. The Total Macular volume, and Best-corrected visual acuity in the two groups showed no significant difference one month after surgery. Amongst the patients who developed postsurgical macular edema, four patients did not possess a positive history for diabetic retinopathy and 3 of them had Non Proliferative Diabetic Retinopathy. We found no significant relationship between the post-surgical macula edema with the presence of mild Non Proliferative Diabetic Retinopathy. (Fisher's test, P = 0.321).

Conclusion:  The ocular anti-VEGF therapy substantially reduces macular edema secondary to post-surgical inflammation in diabetic patients. It effectively reduces the central macular thickness although the results are not found to be statistically significant when compared with the control group.

Key Words:  Diabetes mellitus; diabetic macular edema; diabetic retinopathy: Bevacizumab.

Published
2020-11-30
How to Cite
1.
Bodla A, Minahil Kazmi S, Tariq N, Moazzam A, Muneeb Aman M. Effects of Intra-vitreal Injection of Bevacizumab as an Adjunct during Phacoemulsification in Diabetic Maculopathy. pjo [Internet]. 30Nov.2020 [cited 16Jan.2021];37(1). Available from: https://pjo.org.pk/index.php/pjo/article/view/1122
Section
Original Articles